6 documents found, page 1 of 1
Low bone turnover is associated with plain X-ray vascular calcification in pred...
Neto, R; Pereira, L; Magalhães, J; Quelhas-Santos, J; Frazão, JMBackground Vascular calcification (VC) is a common finding in chronic kidney disease (CKD) patients and predicts subsequent cardiovascular morbidity and mortality in this population. Vascular calcification is linked to disordered mineral metabolism and has been associated with bone histomorphometry changes in CKD. However, data on predialysis patients is scarce. Methods A cross-sectional study was conducted on ...
Sclerostin and DKK1 circulating levels associate with low bone turnover in pati...
Neto, R; Pereira, L; Magalhães, J; Quelhas-Santos, J; Martins, S; Carvalho, C; Frazão, JMBackground: Disordered mineral and bone metabolism is a common complication of chronic kidney disease (CKD). Bone biopsy remains the gold standard tool for evaluating renal osteodystrophy (ROD), but it is an invasive procedure. Despite a growing interest in the ability of newer bone biomarkers to discriminate between different forms of ROD, data on pre-dialysis patients are scarce. Methods: A cross-sectional st...
Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors ...
Fonseca, C; Brito, D; Branco, P; Frazão, JM; Silva-Cardoso, J; Bettencourt, PIntroduction and Objectives: Renin-angiotensin-aldosterone system inhibitors (RAASi) are the cornerstone of treatment of heart failure with reduced ejection fraction (HFrEF). RAASi optimization in real-life care is challenged by hyperkalemia, a potentially fatal adverse event, which can necessitate downtitration or discontinuation of RAASi and negatively impact survival in HFrEF. The literature on this problem ...
Old and new calcimimetics for treatment of secondary hyperparathyroidism: Impac...
Pereira, L; Meng, C; Marques, D; Frazão, JMSecondary hyperparathyroidism (SHPT) is associated with increased bone turnover, risk of fractures, vascular calcifications, and cardiovascular and all-cause mortality. The classical treatment for SHPT includes active vitamin D compounds and phosphate binders. However, achieving the optimal laboratory targets is often difficult because vitamin D sterols suppress parathyroid hormone (PTH) secretion, while also p...
Achieving K/DOQI Targets with Cinacalcet in Dialysis Patients with Secondary Hy...
Macário, F; Frazão, JM; Ferreira, A; Weigert, A; Mota, M; Machado, D; Birne, R; Neto, R; Baldaia Moreira, A; Soares, C; Ribeiro, S; Mendes, T; Alves, RSecondary hyperparathyroidism is a common complication of chronic kidney disease. The elevated serum intact parathyroid hormone, phosphorus, calcium and calcium x phosphorus product have been independently associated with an increased relative risk of mortality. The standard therapy for secondary hyperparathyroidism, including active vitamin D analogues and phosphate binders, is often insufficient to allow pati...
Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystroph...
Ferreira, A; Frazão, JM; Monier-Faugere, MC; Gil, C; Galvão, J; Oliveira, C; Baldaia, J; Rodrigues, I; Santos, C; Ribeiro, S; Hoenger, R; Duggal, ADisturbances in mineral metabolism play a central role in the development of renal bone disease. In a 54-wk, randomized, open-label study, 119 hemodialysis patients were enrolled to compare the effects of sevelamer hydrochloride and calcium carbonate on bone. Biopsy-proven adynamic bone disease was the most frequent bone abnormality at baseline (59%). Serum phosphorus, calcium, and intact parathyroid hormone we...